Drugs / GW01-200
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07629258 | Jun 2026 → Jan 2029 expected | metastatic neoplasm | Groovy Medicine (Hangzhou) Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GW01-200 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07629258 ↗ |
| Route | Oral | “GW01-200 tablets will be administered orally.” NCT07629258 ↗ |